10x Genomics Inc. (TXG)
| Bid | 7.59 |
| Market Cap | 999.23M |
| Revenue (ttm) | 610.78M |
| Net Income (ttm) | -182.63M |
| EPS (ttm) | -1.52 |
| PE Ratio (ttm) | -5.34 |
| Forward PE | -7.15 |
| Analyst | Hold |
| Ask | 8.12 |
| Volume | 2,180,517 |
| Avg. Volume (20D) | 3,504,160 |
| Open | 8.30 |
| Previous Close | 8.27 |
| Day's Range | 8.07 - 8.38 |
| 52-Week Range | 6.78 - 28.25 |
| Beta | 2.01 |
About TXG
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene...
Analyst Forecast
According to 16 analyst ratings, the average rating for TXG stock is "Hold." The 12-month stock price forecast is $18, which is an increase of 121.81% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · businesswire.com
Vizgen Announces End of Litigation with 10x Genomics and Harvard UniversityCAMBRIDGE, Mass.--(BUSINESS WIRE)-- #neuroscience--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released an op...
1 month ago · newsfilecorp.com
Torex Gold Reports First Copper Concentrate Production from Media LunaProcessing plant tie-ins and restart complete; commercial production expected in coming weeks(All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - March 2...
